Hyaluronidase Market Outlook:
Hyaluronidase Market size was over USD 1.8 billion in 2025 and is estimated to reach USD 6.4 billion by the end of 2035, expanding at a CAGR of 15.2% during the forecast timeline, i.e., 2026-2035. In 2026, the industry size of hyaluronidase is assessed at USD 2 billion.
The worldwide market is witnessing a significant transformation, readily evolving from a niche surgical aid to a severe enabler of modernized biologic drug delivery. This particular enzyme is currently at the forefront of pharmaceutical advancement, driven by the need for cost-effective and patient-friendly treatment modalities. Besides, according to an article published by NLM in June 2025, intravenous biologics have been readily approved with investigational hyaluronidase versions, including atezolizumab, with a Medicare spending of USD 819 million, which was cleared in September 2024. Likewise, Efartigimod alfa, with a USD 154 million Medicare cost, was approved in June 2023, thus suitable for boosting the market’s exposure.
Furthermore, the rise of drug-device combinations, expansion in aesthetic reversal, technological purity focus, and transition towards subcutaneous biologics are also uplifting the global market. As per an article published by ACS Publications in January 2023, the international pharmaceutical drug delivery market is expected to reach USD 2,206.5 billion, along with a 5.9% growth rate by the end of 2026. This has readily resulted in drug delivery advancements, featuring standard efforts to deliver biologics. For instance, conjugating polyethylene glycol increased their circulation duration for almost 20 PEGylated protein formulations, which is readily uplifting the market’s development.
